Neuropediatrics 2003; 34(5): 237-246
DOI: 10.1055/s-2003-43254
Original Article

Georg Thieme Verlag Stuttgart · New York

Quantitative Proton Magnetic Resonance Spectroscopy of Children with Adrenoleukodystrophy Before and After Hematopoietic Stem Cell Transplantation

B. Wilken 1 , P. Dechent 2 , K. Brockmann 1 , J. Finsterbusch 2 , M. Baumann 1 , W. Ebell 3 , G. C. Korenke 1 , P. J. W. Pouwels 2 , F. A. Hanefeld 1 , J. Frahm 2
  • 1Abteilung Kinderheilkunde, Schwerpunkt Neuropädiatrie, Georg-August-Universität Göttingen, Germany
  • 2Biomedizinische NMR Forschungs GmbH am Max-Planck-Institut für biophysikalische Chemie, Göttingen, Germany
  • 3Universitäts-Kinderklinik, Charité, Berlin, Germany
Further Information

Publication History

Received: February 27, 2003

Accepted after Revision: May 22, 2003

Publication Date:
04 November 2003 (online)

Abstract

About 35 - 40 % of boys with X-linked adrenoleukodystrophy (ALD) develop a rapidly progressive cerebral form which leads to severe neurologic disability and death within 3 - 5 years after onset of clinical symptoms. Because previous proton magnetic resonance spectroscopy (MRS) studies of ALD identified metabolite patterns characteristic of demyelination, gliosis, and neuroaxonal loss, this work tested the hypothesis that MRS - apart from indicating disease progression - provides criteria for the outcome after hematopoietic stem cell transplantation (HSCT) which has been promising at an early stage of the active disease. Follow-up quantitative proton MRS was performed in frontal and occipital white matter of ALD patients (n = 12) before and up to 5 years after HSCT. The observed metabolite alterations were retrospectively correlated with the clinical outcome representing either a stable condition (n = 5), a further deterioration (n = 5), or death (n = 2). While disease progression of patients before HSCT was mainly characterized by a further increase of elevated choline-containing compounds (Cho) as an indicator of active demyelination, a positive outcome after HSCT was correlated with high N-acetylaspartate (tNAA) levels in affected white matter before HSCT yielding positive and negative predictive values for tNAA of 80 %. Although to be confirmed in a larger cohort of patients, the present findings suggest the preservation of neuroaxonal integrity as a prerequisite for an arrested course. Conversely, the combination of increased Cho with markedly reduced tNAA before HSCT apparently reflects a degree of tissue degeneration which precludes a successful therapeutic intervention.

References

  • 1 Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, Naud-Saudreau C. et al . Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation.  N Engl J Med. 1990;  322 1860-1866
  • 2 Baumann M, Korenke G C, Weddige-Diedrichs A, Wilichowski E, Hunneman D H, Wilken B. et al . Hematopoietic stem cell transplantation in 12 patients with cerebral X-linked adrenoleukodystrophy.  Eur J Pediatr. 2003;  162 6-14
  • 3 Bezman L, Moser H W. Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes.  Am J Med Genet. 1998;  76 415-419
  • 4 Birken D L, Oldendorf W H. N-Acetyl-L-aspartic acid: a literature review of a compound prominent in 1H NMR spectroscopic studies of brain.  Neurosci Biobehav Rev. 1989;  13 23-31
  • 5 Bjartmar C, Battistuta J, Terada N, Dupree E, Trapp B D. N-Acetylaspartate is an axon-specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve.  Ann Neurol. 2002;  51 51-58
  • 6 Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells.  Dev Neurosci. 1993;  15 289-298
  • 7 Dubois-Dalcq M, Feigenbaum V, Aubourg P. The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder.  Trends Neurosci. 1999;  22 4-12
  • 8 Eichler F S, Barker P B, Cox C, Edwin D, Ulug A M, Moser H W, Raymand G V. Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy.  Neurology. 2002;  58 901-907
  • 9 Frahm J, Michaelis T, Merboldt K D, Bruhn H, Gyngell M L, Hänicke. Improvements in localized proton NMR spectroscopy of human brain. Water suppression, short echo times, and 1 mL resolution.  J Magn Reson. 1990;  90 464-473
  • 10 Frahm J, Hanefeld F. Localized proton magnetic resonance spectroscopy of brain disorders in childhood. Bachelard HS Advances in Neurochemistry. Vol. 8. New York; Plenum 1997: 329-402
  • 11 Korenke G C, Christen H J, Hunnemann D H, Hanefeld F. Failure of beta interferon therapy in X-linked adrenoleukodystrophy.  Eur J Pediatr. 1996;  155 833
  • 12 Korenke G C, Pouwels P JW, Frahm J, Hunneman D H, Stoeckler S, Krasemann E. et al . Arrested cerebral adrenoleukodystrophy: A clinical and proton magnetic resonance spectroscopy study in three patients.  Pediatr Neurol. 1996;  15 103-107
  • 13 Loes D J, Hite S, Moser H, Stillman A E, Shapiro E, Lockman L. et al . Adrenoleukodystrophy: A scoring method for brain MR observations.  AJNR. 1994;  15 1761-1766
  • 14 Loes D J, Stillman A E, Hite S, Shapiro E, Lockman L, Latchaw R E. et al . Childhood cerebral form of adrenoleukodystrophy: Short-term effect of bone marrow transplantation on brain MR observations.  AJNR. 1994;  15 1767-1771
  • 15 Malm G, Ringdén O, Anvret M, von Dobeln U, Hagenfeldt L, Isberg B. et al . Treatment of adrenoleukodystrophy with bone marrow transplantation.  Acta Pediatr. 1997;  86 484-492
  • 16 Moser H W, Tutschka P J, Brown F R, Moser A E, Yeager A M, Singh I. et al . Bone marrow transplant in adrenoleukodystrophy.  Neurology. 1984;  34 1410-1417
  • 17 Moser H W. Adrenoleukodystrophy: Phenotype, genetics, pathogenesis and therapy.  Brain. 1997;  120 1485-1508
  • 18 Moser H W, Bezman L, Lu S E, Raymond G V. Therapy of X-linked adrenoleukodystrophy: Prognosis based upon age and MRI abnormality and plans for placebo-controlled trials.  J Inherit Metab Dis. 2000;  23 273-277
  • 19 Moser H W, Loes D J, Melhem E R, Raymond G V, Bezman L, Cox C S. et al . X-Linked adrenoleukodystrophy: Overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients.  Neuropediatrics. 2000;  31 227-239
  • 20 Mosser J, Douar A M, Sarde C O, Kioschis P, Feil R, Moser H. et al . Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters.  Nature. 1993;  361 726-730
  • 21 Pouwels P JW, Kruse B, Korenke G C, Mao X, Hanefeld F A, Frahm J. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy.  Neuropediatrics. 1998;  29 1-11
  • 22 Pouwels P JW, Brockmann K, Kruse B, Wilken B, Wick M, Hanefeld F. et al . Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS.  Pediatr Res. 1999;  46 474-485
  • 23 Provencher S W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra.  Magn Reson Med. 1993;  30 672-679
  • 24 Shapiro E, Krivit W, Lockman L, Jambaque I, Peters C, Cowan M. et al . Long-term effect of bone marrow transplantation for childhood onset cerebral X-linked adrenoleukodystrophy.  Lancet. 2000;  356 713-718
  • 25 Smith K D, Kemp S, Braiterman L T, Lu J F, Wei H M, Geraghty M. et al . X-linked adrenoleukodystrophy: Genes, mutations, and phenotypes.  Neurochem Res. 1999;  24 521-535
  • 26 Suzuki Y, Isogai K, Teramoto T, Tashita H, Shimozawa N, Nishimura M. et al . Bone marrow transplantation for the treatment of X-linked adrenoleukodystrophy.  J Inherit Metab Dis. 2000;  23 453-458
  • 27 Suzuki Y, Imamura A, Shimozawa N, Kondo N. The clinical course of childhood and adolescent adrenoleukodystrophy before and after Lorenzo's oil.  Brain Dev. 2001;  23 30-33
  • 28 Wilken B, Dechent P, Herms J, Maxton C, Markakis E, Hanefeld F. et al . Quantitative proton magnetic resonance spectroscopy of focal brain lesions.  Pediatr Neurol. 2000;  23 22-31

Prof. Dr. Jens Frahm

Biomedizinische NMR Forschungs GmbH am Max-Planck-Institut für biophysikalische Chemie

37070 Göttingen

Germany

Email: jfrahm@gwdg.de

    >